Compare RVTY & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVTY | SF |
|---|---|---|
| Founded | 1937 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Bankers/Brokers/Service |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.4B |
| IPO Year | 1994 | N/A |
| Metric | RVTY | SF |
|---|---|---|
| Price | $89.65 | $77.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $111.87 | $90.33 |
| AVG Volume (30 Days) | 908.7K | ★ 1.3M |
| Earning Date | 04-27-2026 | 04-22-2026 |
| Dividend Yield | 0.31% | ★ 1.76% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,311,822,000.00 | N/A |
| Revenue This Year | $6.34 | $17.04 |
| Revenue Next Year | $5.14 | $7.61 |
| P/E Ratio | $43.76 | ★ $20.53 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.36 | $69.31 |
| 52 Week High | $118.30 | $134.74 |
| Indicator | RVTY | SF |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 45.10 |
| Support Level | $88.73 | $69.31 |
| Resistance Level | $95.90 | $116.74 |
| Average True Range (ATR) | 2.96 | 2.04 |
| MACD | 0.93 | 2.22 |
| Stochastic Oscillator | 64.67 | 91.63 |
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.